Cyclerion Therapeutics, Inc. (24)

Browse by Contract Category

Contracts

Cyclerion Therapeutics, Inc. Executive Severance Plan (Filed With SEC on August 9, 2022)
Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Cheryl Gault (Filed With SEC on May 4, 2022)
Lease Termination Agreement, dated as of April 30, 2021, by and between BMR-Rogers Street LLC and the Company (Filed With SEC on May 4, 2021)
Common Stock Purchase Agreement dated as of July 29, 2020, by and between Cyelerion Therapeuties, Inc. and he Investors Named Therein (Filed With SEC on August 3, 2020)
Intellectual Property License Agreement, dated as of April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
Development Agreement, dated as of April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
Non-Employee Director Compensation Plan (amended and restated as of December 17, 2021) (Filed With SEC on May 4, 2022)
Employment Agreement, effective April 29, 2019, by and between Cyclerion GmbH and Andreas Busch (Filed With SEC on May 4, 2022)
Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 24, 2022)
Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 25, 2021)
Open Market Sale AgreementSM, dated September 3, 2020, by and between Cyclerion Therapeutics, Inc. and Jefferies LLC (Filed With SEC on September 3, 2020)
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 12, 2020)
First Amendment to and Partial Termination of Lease Agreement Lease, dated April 1, 2019, by and between BMR-Rogers Street LLC and the Company (Filed With SEC on March 5, 2020)
Cyclerion Therapeutics, Inc. Executive Severance Plan (Filed With SEC on September 25, 2019)
Non-Employee Director Compensation Plan (effective June 1, 2019) (Filed With SEC on August 12, 2019)
Transition Services Agreement, dated as of April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Ironwood Pharmaceuticals, Inc (Filed With SEC on April 2, 2019)
Separation Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
Lease, dated April 1, 2019, by and between BMR-Rogers Street LLC and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and William Huyett (Filed With SEC on April 2, 2019)
Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Mark G. Currie, Ph.D (Filed With SEC on April 2, 2019)
Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Peter M. Hecht, Ph.D (Filed With SEC on April 2, 2019)
Employee Matters Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
Tax Matters Agreement, dated as of March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)
Transition Services Agreement, dated as of April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc (Filed With SEC on April 2, 2019)